High baseline interleukine-8 level is an Independent risk factor for the achievement of sustained virological response in chronic HCV patients

Infection, Genetics and Evolution

Volumn 11, Issue 6, 2011, Pages 1301-1305

  Akbar, Haji ^a,b   Idrees, Muhammad ^a   Butt, Sadia ^a   Awan, Zunaira ^a   Sabar, Muhammd Farooq ^a   Rehaman, Irshad ur ^a   Hussain, Abrar ^a   Saleem, Sana ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b Department of Electrical Computer Engineering   (Pakistan)

Author keywords

Hepatitis C; IFN ; IL 8; Ribavirin therapy; Risk factor

Indexed keywords

INTERLEUKIN 8; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PAKISTAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; RISK FACTOR; VIRUS LOAD; VIRUS PATHOGENESIS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I; INTERLEUKIN-8; MALE; MIDDLE AGED; PAKISTAN; REFERENCE VALUES; RIBAVIRIN; RISK FACTORS; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 79960403248     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2011.04.021     Document Type: Article

References (41)

1. Akbar H., Idrees M., Manzoor S., Rehman I.U., Butt S., Yousaf M.Z., Rafique S., Awan Z., Khubaib B., Akram M., Aftab M. Hepatitis C virus infection: a review of the current and future aspects and concerns in Pakistan. J. Gen. Mol. Virol. 2009, 1(2):12-18.
2. Balasubramanian A., Ganju R.K., Groopman J.E. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. J. Biol. Chem. 2003, 278:35755-35766.
3. Balasubramanian A., Munshi N., Koziel M.J., Hu Z., Liang T.J., Groopman J.E., Ramesh K., Ganju R.K. Structural proteins of hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells. J. Gen. Virol. 2005, 86:3291-3301.
4. Farhana M., Hussain I., Haroon T.S. Hepatitis C: the dermatologic profile. J. Pak. Assoc. Dermtol. 2009, 18:171-181.
5. Fiorucci M., Boulant S., Fournillier A., Abraham J.D., Lavergne J.P., Paranhos-Baccala G., Inchauspe G., Bain C. Expression of the alternative reading frame protein of Hepatitis C virus induces cytokines involved in hepatic injuries. J. Gen. Virol. 2007, 88:1149-1162.
6. Gale M.J., Korth M.J., Tang N.M., Tan S.L., Hopkins D.A., Dever T.E., Polyak S.J., Gretch D.R., Katze M.G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997, 230:217-227.
7. Gerotto M., Sullivan D.G., Polyak S.J., Chemello L., Cavalletto L., Pontisso P., Alberti A., Gretch D.R. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasi species diversification in nonresponder patients with chronic hepatitis C. J. Virol. 1999, 73(9):7241-7247.
8. Giannini C., Brechot C. Hepatitis C virus biology cell death and differentiation. Cell Death Diff. 2003, 10(1):S27-38.
9. Gonzalez-Peralta R.P., Qian K., She J.Y., Davis G.L., Ohno T., Mizokami M., Lau J.Y.N. Clinical implications of viral quasi species heterogeneity in chronic hepatitis C. J. Med. Virol. 1996, 49:242-247.
10. Hanley J.P., Lisa M., Jarvis L.M., Andrews J., Dennis R., Peter C., Hayes P.C., Piris J., Lee R. Interferon treatment for chronic hepatitis C infection in hemophiliacs-influence of virus load genotype, and liver pathology on response. Blood 1996, 87(5):1704-1709.
11. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
12. Idrees M., Lal A., Naseem M., Khalid M. High prevalence of hepatitis C virus infection in the largest province of Pakistan. J. Dig. Dis. 2008, 9:95-103.
13. Idrees M., Riazuddin S. A study of best positive predictors for sustained virological response to interferon alpha plus ribavirin therapy in naïve hepatitis C patients. BMC Gastroenterol. 2009, 5-9.
14. Idrees M., Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect. Dis. 2008, 8-69.
15. Idrees M. Development of an improved genotyping assay for the detection of hepatitis C virus genotype and subtypes in Pakistan. J. Virol. Methods 2008, 150:50-56.
16. Jacobs J.M., Diamond D.L., Chan E.Y., Gristenko M.A., Qian W., Stastna M., Bass T., CampII D.G., Carithers R.L., Smith R.D., Katze M.G. Proteome Analysis of full-length hepatitis C virus (HCV) replication and specimens of post-transplantation liver from HCV infected patients. JVI 2005, 79(12):7558-7569.
17. Kadoya H., Nagano-Fujii M., Deng L., Nakazono N., Hotta H. Nonstructural proteins 4A and 4B of hepatitis C virus transactivate the interleukin 8 promoter. Microbiol. Immunol. 2005, 49:265-273.
18. Kanazawa Y., Hayashi N., Mita E., Li T., Hagiwara H., Kasahara A., Fusamoto H., Kamada T. Influence of viral quasi species on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994, 20:1121-1130.
19. Kato N., Yoshida H., Kioko O., Kato J., Goto T., Otsuka M., Lan K., Matsushima K., Shiratori Y., Omata M. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000, 32:405-412.
20. Kato N. Molecular virology of hepatitis C virus. Acta. Med. Okayama 2001, 55(3):133-159.
21. Katze M.G. Regulation of the interferon-induced PKR: can viruses cope?. Trends Microbiol. 1995, 3:75-78.
22. Khabar K.S., Murayama T., Al-Ahdal M.N., Mukaida N., Matsushima N. Interleukin-8 is induced by viruses, enhances cytomegalovirus and picornavirus replication, and inhibits the antiviral action of interferonalpha. Advances in Animal Virology 2000, 323-337. Oxford and IBH Publishing Co., New Delhi, India. S. Jameel, L. Villarreal (Eds.).
23. Malaguarnera M., DiFazio I., Romeo M.A., Restuccia S., Laurino A., Trovato B.A. Elevation of IL6 levels in patients with chronic hepatitis due to hepatitis C virus. J. Gastroenterol. 1997, 32:211-215.
24. Moribe T., Hayashi N., Kanazawa Y., Mita E., Fusamoto H., Negi M., Kaneshige T., Igimi T., Kamada T., Uchida K. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995, 108:789-795.
25. Neuman M.G., Benhamou J.P., Martinot M., Boyer N., Shear N.H., Malkiewicz I., Katz G.G., Suneja A., Singh S., Marcellin P. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin. Biochem. 1999, 32(7):537-545.
26. Neuman M.G., Benhamou J.P., Shear N.H. Interleukine 6 normalization during interferon-ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 1999, 30(Suppl. 1):242. PC06/49.
27. Neuman M.G., Benhamou J.P., Shear N.H. Serum tumor necrosis factor as a predictor of sustain response to alpha-interferon-ribavirin combination therapy in chronic hepatitis C. J Hepatol 1999, 30(Suppl. 1):257. PC06/109.
28. Oem J.K., Jackel C.J., Li Y.P., Kang H.N., Zhou Y., Babiuk L.A., Liu Q. Hepatitis C virus non-structural protein-2 activates CXCL-8 transcription through NF-kB. Arch. Virol. 2008, 153:293-301.
29. Okada S., Akahane Y., Suzuki H., Okamoto H., Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992, 16:619-624.
30. Polyak S.J., Faulkner G., Carithers R., Corey L., Gretch D. Assessment of hepatitis C virus quasi species heterogeneity by gel shift analysis: correlation with response to interferon therapy. J. Infect. Dis. 1997, 175:1101-1107.
31. Polyak S.J., Gerotto M. Molecular basis of responsiveness to interferon in hepatitis C. Trends Exp. Clin. Med. Forum 2000, 10:46-58.
32. Polyak S.J., Khabar K.S., Paschal D.M., Ezelle H.J., Duverlie G., Barber G.N., Levy D.E., Mukaida N., Gretch D.R. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 2001, 75(13):6095-6106.
33. Polyak S.J., Khabar K.S., Rezeiq M., Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 2001, 75(13):6209-6211.
34. Polyak S.J., Nousbaum J.B., Larson A.M., Cotler S., Carithers J.R.L., Gretch D.R. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. J. Infect. Dis. 2000, 182(2):204-397.
35. Polyak S.J., Paschal D.M., Mcardle S., Gale M.J., Moradpour D., Gretch D.R. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999, 29:1262-1271.
36. Quiroga J.A. Induction of interlekin-12 production in chronic hepatis C virus infection correlates with the hepatocellular damage. J. Infect. Dis. 1998, 178:247-251.
37. Sarwat A., Naeem M., Hussain A., Kakar N., Babar M.E., Ahmad J. Prevalence of hepatitis C virus (HCV) genotypes in Balochistan. Mol. Biol. Rep. 2008, 10.1007/s11033-008-9342-0.
38. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
39. Tang H., Grise H. Cellular and molecular biology of HCV infection and hepatitis. Clin. Sci. (Lond.) 2009, 117(2):49-65.
40. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-110.
41. Zylberberg H.R., Pol S., Masson A., et al. Soluble tumor necrosis factors in chronic hepatitis C: a correlation with histological fibrosis and activity. J. Hepatol. 1999, 30:185-191.